Regeneron Pharmaceuticals Inc. buy Guggenheim
Summary
This prediction is currently active. The BUY prediction by Guggenheim currently has a performance of 14.45%. A total of €1.82 was paid as dividends for this prediction. This prediction currently runs until 29.10.26. The prediction end date can be changed by Guggenheim at any time. Guggenheim has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.506% | -3.506% |
| iShares Core DAX® | 0.789% | 1.975% |
| iShares Nasdaq 100 | 4.226% | 4.344% |
| iShares Nikkei 225® | 3.285% | 6.991% |
| iShares S&P 500 | 2.496% | 2.759% |
Comments by Guggenheim for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Guggenheim for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
09.02.26
09.02.27
07:30
Regeneron Pharmaceuticals Inc.
30.05.25
30.05.26
07:30
Regeneron Pharmaceuticals Inc.
01.05.25
01.05.26
07:30
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
03.08.25
Regeneron Pharmaceuticals Inc.
19.07.24
19.07.25
20.07.25

